Jasper Therapeutics, Inc. (JSPR)
NASDAQ: JSPR · Real-Time Price · USD
5.96
-0.20 (-3.25%)
At close: Feb 21, 2025, 4:00 PM
5.86
-0.10 (-1.68%)
After-hours: Feb 21, 2025, 5:23 PM EST
Jasper Therapeutics Employees
Jasper Therapeutics had 45 employees as of December 31, 2023. The number of employees increased by 10 or 28.57% compared to the previous year.
Employees
45
Change (1Y)
10
Growth (1Y)
28.57%
Revenue / Employee
n/a
Profits / Employee
-$1,411,756
Market Cap
89.41M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 45 | 10 | 28.57% |
Dec 31, 2022 | 35 | 10 | 40.00% |
Dec 31, 2021 | 25 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
JSPR News
- 12 days ago - Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting - GlobeNewsWire
- 18 days ago - Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference - GlobeNewsWire
- 6 weeks ago - Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria - GlobeNewsWire
- 6 weeks ago - Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025 - GlobeNewsWire
- 2 months ago - Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma - GlobeNewsWire
- 3 months ago - Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma - Seeking Alpha
- 3 months ago - Jasper Therapeutics to Participate at Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire